-
CDSCO Panel Approves Novartis Healthcare's Protocol Amendment to study Iptacopan
03 May 2025 15:18 GMT
… protocol amendment proposal presented by Novartis Healthcare for Iptacopan (LNP023) study …
-
BMS scales back at former Novartis plant, shifting cell therapy vector production to MA
02 May 2025 18:30 GMT
… years after securing a former Novartis facility in Illinois to support … , which was previously used by Novartis to manufacture the gene therapy … working at the facility after Novartis announced plans to halt operations …
-
Rx Rundown: Merck KGaA, Novartis, Hims & Hers and more
02 May 2025 14:21 GMT
… billion deal for SpringWorks Therapeutics.
Novartis plans to acquire Regulus Therapeutics … should get higher Medicare reimbursements.
Novartis reported better-than-expected Q1 …
-
Novartis to buy Regulus Therapeutics for as much as $1.7 billion
02 May 2025 13:55 GMT
Novartis AG agreed to buy US … genetic cause of renal failure.
Novartis is hunting for deals that … control the function of cells.
Novartis’s global development and commercial … to trade about 131% higher. Novartis stock was largely flat in …
-
Novartis inks agreement to buy Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD
02 May 2025 08:58 GMT
… and chief medical officer, Novartis. “ADPKD is the most … wholly owned subsidiary of Novartis.
The transaction is expected … approvals. Until closing, Novartis and Regulus will continue … with innovations in transplantation, Novartis is dedicated to transforming …
-
Novartis to acquire Regulus in $1.7B kidney drug deal
01 May 2025 20:15 GMT
… , farabursen, gets regulatory approval, Novartis will pay another $900 million … development and chief medical officer, Novartis, commented, “With limited treatment … currently have limited treatment options. Novartis’ established global development and …
-
New $1.7b Novartis acquisition to advance novel microRNA inhibitor
01 May 2025 19:56 GMT
… Development and Chief Medical Officer, Novartis.
Novartis’ new merger deal – advancing … conditions.
Other acquisitions by Novartis
Novartis announced another merger agreement … and Metabolism Development Unit, Novartis, following the acquisition announcement. …
-
Novartis to Acquire Regulus in $1.7 Billion Deal
01 May 2025 20:07 GMT
-
Novartis to expand renal disease pipeline with $1.7bn Regulus acquisition
01 May 2025 11:18 GMT
… pipeline.
The agreement will give Novartis access to farabursen, a … development and chief medical officer, Novartis, said farabursen “represents a potential … currently have limited treatment options.
“Novartis’ established global development and commercial …
-
Novartis to strengthen renal disease portfolio with Regulus
01 May 2025 10:33 GMT
… companies’ boards of directors.
Novartis will commence a tender … therapy.
Post completion, Novartis plans to combine the … safety and clinical efficacy.
Novartis Development president and chief medical … .”
In February 2025, Novartis agreed to acquire Anthos …
About
© 1995-2025